Virology News and Research

Latest Virology News and Research

New microneedle patch simplifies measles vaccination

A new microneedle patch being developed by the Georgia Institute of Technology and the Centers for Disease Control and Prevention (CDC) could make it easier to vaccinate people against measles and other vaccine-preventable diseases.

28 Apr 2015

Will new hepatitis C treatments strain payers’ budgets? An interview with Dr Chhatwal

Our analysis shows that these drugs would not save overall healthcare money, but would add to the budget. When something is cost effective, it does not necessarily mean it is going to save money. It essentially implies that we're willing to spend additional money to gain additional benefits...

28 Apr 2015

Gas naturally produced within our bodies reduces severity of RSV infection, UTMB study finds

A new study from the University of Texas Medical Branch at Galveston is the first to show that hydrogen sulfide, a gas produced naturally within our bodies, reduces the severity of respiratory syncytial virus, or RSV.

28 Apr 2015

OpenMRS community drives the world's largest open source project to tackle Ebola virus

An accurate, up to the minute, accessible medical record system is fundamental to effective treatment and tracking of the Ebola virus.

28 Apr 2015

NanoViricides' anti-viral drug candidates show promise in lethal animal model of dermal herpes infection

NanoViricides, Inc., a nanomedicine company developing anti-viral drugs, discusses the significance of the strong effectiveness demonstrated by its anti-viral drug candidates in a lethal animal model of dermal herpes infection.

27 Apr 2015

Combination therapy effective in HCV patients with advanced cirrhosis and post-transplant recurrence

Phase 3 results presented today at The International Liver Congress 2015 show that a combination of daclatasvir (DCV), sofosbuvir (SOF) and ribavirin (RBV) for 12 weeks was effective and well tolerated amongst patients with hepatitis C virus (HCV) infection with advanced cirrhosis and post-transplant recurrence.

27 Apr 2015

Sofosbuvir-based regimens effective in HIV-HCV co-infected, cirrhotic patients

A new study revealed today at The International Liver Congress 2015 shows that sofosbuvir (SOF)-based regimens are effective and well tolerated in hepatitis C and HIV co-infected, cirrhotic patients. Sustained virologic response at 4 weeks (SVR4) was observed in 98% of patients and in 95% at 12 weeks (SVR12).

27 Apr 2015

National Immunization Awareness Week launched by the Honourable Rona Ambrose, Minister of Health

Today, the Honourable Rona Ambrose, Minister of Health, and Dr. Gregory Taylor, Canada's Chief Public Health Officer, launched National Immunization Awareness Week, which runs from April 25 to May 2. They encouraged Canadians to stay healthy by making sure their vaccinations are up to date.

27 Apr 2015

Combination treatment effective for HCV genotype-1 mono-infected patients

Results presented today at The International Liver Congress 2015 show that the sofosbuvir (SOF)/daclatasvir (DCV) treatment combination is effective amongst hepatitis C virus (HCV) genotype-1 mono-infected patients. These results are significant because whilst other combinations have been widely reported on, there have been few data until now regarding the use of SOF/DCV combination in real world situations.

25 Apr 2015

New data supports use DAAs in patients with HCV recurrence following liver transplantation

New data presented today at The International Liver Congress 2015, supports the use of sofosbuvir (SOF)- and daclatasvir (DCV)-based regimens in patients with recurrence of the hepatitis C virus (HCV) following liver transplantation (LT).

25 Apr 2015

Occurrence of advanced liver fibrosis similar for patients with HCV infection

Study results presented today at The International Liver Congress 2015 show that the occurrence of advanced liver fibrosis is similar for patients infected with the hepatitis C virus (HCV), whether or not they have been diagnosed.

25 Apr 2015

AUDs have negative prognostic outcome with higher mortality risks in patients with HCV infection

Results presented today at The International Liver Congress 2015, show that alcohol use disorders (AUD) have a serious, negative prognostic outcome with higher mortality risks in the general population and patients with hepatitis C virus (HCV) infection in particular.

25 Apr 2015

Scientists discover new way to control inflammation during worm infections and allergies

Research from The University of Manchester is bringing scientists a step closer to developing new therapies for controlling the body's response to allergies and parasitic worm infections.

25 Apr 2015

AbbVie's all-oral, interferon-free therapy granted FDA priority review for treatment of GT4 HCV infection

AbbVie has announced that the U.S. Food and Drug Administration has accepted its New Drug Application (NDA) and granted priority review for the company's, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV).

25 Apr 2015

Study: Cancer rates in HCV patients significantly increase compared to non-HCV cohort

Results announced today at The International Liver Congress 2015 show that cancer rates in patients with the hepatitis C virus (HCV) were significantly increased compared to the non-HCV cohort. The researchers suggest an extrahepatic manifestation of HCV may be an increased risk of cancer.

25 Apr 2015

Metanome changes name to Diversigen

Metanome, Inc., an industry leader in comprehensive microbiome services, today announced the company has changed its name to Diversigen, Inc. The name was changed to reflect Diversigen's positioning as the single commercial source for the myriad of services and expertise customers need to capitalize on the diverse opportunities of the microbiome.

23 Apr 2015

Study highlights need to increase current levels of interventions to reduce HBV transmission

Results revealed today at The International Liver Congress 2015 demonstrate current treatment and prevention programmes need to be scaled up in order to make elimination of hepatitis B virus (HBV) possible.

23 Apr 2015

Daclatasvir-sofosbuvir treatment highly effective in patients with HCV and HIV co-infection

Phase III results revealed today at The International Liver Congress 2015 show that once-daily treatment with daclatasvir (DCV) plus sofosbuvir (SOF) resulted in an overall 97% sustained virologic response (SVR) at 12 weeks post-treatment in patients with hepatitis C virus (HCV) and HIV co-infection, including cirrhotic patients.

23 Apr 2015

Study: Combination therapy shows high SVR rates in HCV patients with decompensated liver disease

Results presented today at The International Liver Congress 2015 show that the use of the fixed-dose combination of ledipasvir/sofosbuvir (LDV/SOF) in combination with ribavirin (RBV) was well tolerated and demonstrated high sustained virologic response rates 12 weeks post treatment (SVR12) in patients with chronic hepatitis C virus (HCV) infection who have decompensated liver disease (cirrhosis) or have undergone liver transplantation.

23 Apr 2015

Survey: Nearly half of people infected with viral hepatitis suffer discrimination

As many as half of people infected with viral hepatitis have suffered discrimination and one-quarter admit that family members have avoided physical contact with them after finding out they had the infection. A shocking patient survey presented at The International Liver Congress 2015 has shown the devastating impact the infection has on their daily lives.

23 Apr 2015

Virology News and Research

Latest Virology News and Research

New microneedle patch simplifies measles vaccination

Will new hepatitis C treatments strain payers’ budgets? An interview with Dr Chhatwal

Gas naturally produced within our bodies reduces severity of RSV infection, UTMB study finds

OpenMRS community drives the world's largest open source project to tackle Ebola virus

NanoViricides' anti-viral drug candidates show promise in lethal animal model of dermal herpes infection

Combination therapy effective in HCV patients with advanced cirrhosis and post-transplant recurrence

Sofosbuvir-based regimens effective in HIV-HCV co-infected, cirrhotic patients

National Immunization Awareness Week launched by the Honourable Rona Ambrose, Minister of Health

Combination treatment effective for HCV genotype-1 mono-infected patients

New data supports use DAAs in patients with HCV recurrence following liver transplantation

Occurrence of advanced liver fibrosis similar for patients with HCV infection

AUDs have negative prognostic outcome with higher mortality risks in patients with HCV infection

Scientists discover new way to control inflammation during worm infections and allergies

AbbVie's all-oral, interferon-free therapy granted FDA priority review for treatment of GT4 HCV infection

Study: Cancer rates in HCV patients significantly increase compared to non-HCV cohort

Metanome changes name to Diversigen

Study highlights need to increase current levels of interventions to reduce HBV transmission

Daclatasvir-sofosbuvir treatment highly effective in patients with HCV and HIV co-infection

Study: Combination therapy shows high SVR rates in HCV patients with decompensated liver disease

Survey: Nearly half of people infected with viral hepatitis suffer discrimination

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production